Keyword: Valeant Pharmaceuticals
After a meeting with the FDA, Bausch Health is back on track with psoriasis candidate Duobrii sooner than some analysts expected.
More and more postscandal drugmakers are landing on the same solution for restoring their good name: Change it.
What do you do when you need growth, and one drug is far and away your biggest? GIve that product as much fuel as possible.
US WorldMeds needed a partner to help launch its first-ever opioid withdrawal med Lucemyra, and Valeant’s Salix has taken the job.
Wells Fargo analyst depicted the rejection as “a major setback” for Valeant that puts a dent in the company’s five-year growth plan.
Now that former shareholders of Sprout have the company back in their hands, they’ve reinstalled a familiar face at the helm.
A jury today found a former exec of mail order pharmacy Philidor and a former Valeant Pharmaceuticals exec guilty of defrauding the drugmaker.
A former Valeant executive suspected an illicit relationship between a colleague and mail order pharmacy Philidor, he testified.
Valeant is getting a new name and stock ticker to press ahead after its storied downfall.
With news of a refinancing and management change, Concordia shares plunged deeper into penny-stock territory.